Due to the prevalence of EGFR and PDGFRA amplified tumour cells in GBMs, occurring in 43% and 11% of GBM samples in The Cancer Genome Atlas (TCGA) database, respectively [19], these sub-populations have become prime molecular targets for therapies and a number of inhibitor drugs have been developed for this purpose [5]. This evidence concerns the gene EGFR and neoplasm.